AstraZeneca partners with Alveofit to scale up the diagnosis of lung diseases in India

As a part of this partnership with Alveofit, AstraZeneca will provide Alveofit IoT enabled handheld spirometers to the clinics and hospitals to enable point of care spirometry for optimised management of different lung associated non-communicable diseases

Under the aegis of its A.Catalyst network, AstraZeneca India announced its partnership with Alveofit, a SaaS-IoT enabled respiratory healthcare platform, to offer IoT enabled handheld spirometers at hospitals across the country.

This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.

As a part of this partnership with Alveofit, AstraZeneca will provide Alveofit IoT enabled handheld spirometers to the clinics and hospitals to enable point of care spirometry for optimised management of different lung associated non-communicable diseases. This will help track patients remotely and even conduct telespirometry with comprehensive care management solutions.

A.Catalyst Network is an interconnected and dynamic global network of more than 20 AstraZeneca health innovation hubs, made up of physical locations and virtual partnerships. As a part of the partnership with Alveofit, AstraZeneca has deployed spirometers at selected hospitals across the country. This include ESIC hospitals for industrial employees, command and military hospitals, general hospitals and last mile clinics in cities like Lucknow, Chennai, Nagpur, Delhi, Ahmedabad and Kolkata. In a pilot project conducted before starting this initiative, 2800+ patients were tested and around 35-40 per cent were diagnosed with lung issues across all the age groups right from 10-12 year old to 85-90 year old through this deployment.

Alveofit won the JANCare Innovation Challenge that was organised jointly by BIRAC and NASSCOM CoE, a partner of ISHIC.